3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Advanced Solid Tumor
3
Neoplasm Metastasis
2
Melanoma
2
Esophageal Squamous Cell Carcinoma
2
Advanced Solid Tumour
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Simpson-Golabi-Behmel syndrome
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Metastatic Solid Tumors
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Diabetes Mellitus
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Advanced Solid Tumors
1
Advanced Malignancies
1
Adenocarcinoma Of Esophagus
1
Interventions
lutetium Lu 177 dotatate
8
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
pembrolizumab
3
olaparib
2
fludarabine
2
cabozantinib
2
X-Rays
2
Phantoms, Imaging
2
Cyclophosphamide
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
repotrectinib
1
peposertib
1
pazopanib
1
lenvatinib
1
fludarabine phosphate
1
entrectinib
1
belinostat
1
atezolizumab
1
aldesleukin
1
Yttrium-90
1
Tomography, X-Ray Computed
1
Tomography, Emission-Computed, Single-Photon
1
Temozolomide
1
Single Photon Emission Computed Tomography Computed Tomography
1
Salts
1
Positron Emission Tomography Computed Tomography
1
PT-100 dipeptide
1
Octreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
tislelizumab
×
30 days
×
Clear all
No trials found.